CRISPR/Cas9 Genome Engineering in Engraftable Human Brain-Derived Neural Stem Cells

[1]  Gang Bao,et al.  A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human haematopoietic stem and progenitor cells , 2018, Nature Medicine.

[2]  K. Anderson,et al.  Emerging Safety of Intramedullary Transplantation of Human Neural Stem Cells in Chronic Cervical and Thoracic Spinal Cord Injury , 2018, Neurosurgery.

[3]  R. Bak,et al.  CRISPR/Cas9 genome editing in human hematopoietic stem cells , 2018, Nature Protocols.

[4]  Andreas Reinisch,et al.  Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6 , 2017, eLife.

[5]  Leslie S. Edwards,et al.  Mapping the genomic landscape of CRISPR–Cas9 cleavage , 2017, Nature Methods.

[6]  Jennifer A. Doudna,et al.  Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery , 2017, Nucleic acids research.

[7]  W. Skarnes,et al.  Efficient CRISPR/Cas9-assisted gene targeting enables rapid and precise genetic manipulation of mammalian neural stem cells , 2017, Development.

[8]  Sruthi Mantri,et al.  CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells , 2016, Nature.

[9]  M. Porteus,et al.  Genome Editing: A New Approach to Human Therapeutics. , 2016, Annual review of pharmacology and toxicology.

[10]  Feng Zhang,et al.  Applications of CRISPR–Cas systems in neuroscience , 2015, Nature Reviews Neuroscience.

[11]  P. Gregory,et al.  Homology-driven genome editing in hematopoietic stem and progenitor cells using zinc finger nuclease mRNA and AAV6 donors , 2015, Nature Biotechnology.

[12]  A. Scharenberg,et al.  Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template , 2015, Science Translational Medicine.

[13]  Israel Steinfeld,et al.  Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells , 2015, Nature Biotechnology.

[14]  A. Ballabio,et al.  Lysosomal storage diseases: from pathophysiology to therapy. , 2015, Annual review of medicine.

[15]  B. van Steensel,et al.  Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.

[16]  Phillip A. Sharp,et al.  Target specificity of the CRISPR-Cas9 system , 2014, Quantitative Biology.

[17]  Gang Bao,et al.  Quantifying genome-editing outcomes at endogenous loci with SMRT sequencing. , 2014, Cell reports.

[18]  R. Lund,et al.  Phagocytosis of photoreceptor outer segments by transplanted human neural stem cells as a neuroprotective mechanism in retinal degeneration. , 2013, Investigative Ophthalmology and Visual Science.

[19]  A. Tsukamoto,et al.  Clinical translation of human neural stem cells , 2013, Stem Cell Research & Therapy.

[20]  Daniel J. Guillaume,et al.  Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis. , 2013, Journal of neurosurgery. Pediatrics.

[21]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[22]  R. Henry,et al.  Neural Stem Cell Engraftment and Myelination in the Human Brain , 2012, Science Translational Medicine.

[23]  Brian J Cummings,et al.  Human Neural Stem Cells Induce Functional Myelination in Mice with Severe Dysmyelination , 2012, Science Translational Medicine.

[24]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[25]  R. Lund,et al.  Transplantation of human central nervous system stem cells – neuroprotection in retinal degeneration , 2012, The European journal of neuroscience.

[26]  M. Bootman,et al.  Non-immortalized human neural stem (NS) cells as a scalable platform for cellular assays , 2011, Neurochemistry International.

[27]  N. Benvenisty,et al.  The tumorigenicity of human embryonic and induced pluripotent stem cells , 2011, Nature Reviews Cancer.

[28]  E. Kass,et al.  Collaboration and competition between DNA double‐strand break repair pathways , 2010, FEBS letters.

[29]  Brian J Cummings,et al.  Human Neural Stem Cells Differentiate and Promote Locomotor Recovery in an Early Chronic Spinal coRd Injury NOD-scid Mouse Model , 2010, PloS one.

[30]  Jens Boch,et al.  Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors , 2009, Science.

[31]  I. Weissman,et al.  Neuroprotection of host cells by human central nervous system stem cells in a mouse model of infantile neuronal ceroid lipofuscinosis. , 2009, Cell stem cell.

[32]  Nobuko Uchida,et al.  Human neural stem cells differentiate and promote locomotor recovery in spinal cord-injured mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  I. Weissman,et al.  Engraftment of sorted/expanded human central nervous system stem cells from fetal brain , 2002, Journal of neuroscience research.

[34]  I. Weissman,et al.  Direct isolation of human central nervous system stem cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[35]  I. Longden,et al.  EMBOSS: the European Molecular Biology Open Software Suite. , 2000, Trends in genetics : TIG.

[36]  M. Carpenter,et al.  In Vitro Expansion of a Multipotent Population of Human Neural Progenitor Cells , 1999, Experimental Neurology.

[37]  D. Wenger,et al.  Characterization of the large deletion in the GALC gene found in patients with Krabbe disease. , 1995, Human molecular genetics.

[38]  D. Wenger,et al.  A large deletion together with a point mutation in the GALC gene is a common mutant allele in patients with infantile Krabbe disease. , 1995, Human molecular genetics.

[39]  C. Ames,et al.  Genetic modification of neural stem cells. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  V. Tybulewicz,et al.  CD19 is essential for B cell activation by promoting B cell receptor–antigen microcluster formation in response to membrane-bound ligand , 2008, Nature Immunology.